Daraxonrasib Pancreatic Cancer Results: A Historic Breakthrough

Original Article by Lisa Jarvis | Bloomberg | 15 April 2026

Daraxonrasib pancreatic cancer trial results show that Revolution Medicines' new therapy is doubling survival rates and reshaping oncology.

Daraxonrasib pancreatic cancer trial results show that Revolution Medicines’ new therapy is doubling survival rates and reshaping oncology.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here